JOSE MAURICIO SEGUNDO CORREIA MOTA

Índice h a partir de 2011
9
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Mostrar mais
Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 26
  • article 0 Citação(ões) na Scopus
    Robotic-assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
    (2024) SUARTZ, Caio Vinicius; MARTINEZ, Lucas Motta; BRITO, Pedro Henrique; NETO, Carlos Victori; CORDEIRO, Mauricio Dener; BOTELHO, Luiz Antonio Assan; GALLUCCI, Fabio Pescarmona; MOTA, Jose Mauricio; NAHAS, William Carlos; RIBEIRO-FILHO, Leopoldo Alves
    Introduction Surgical intervention is the treatment of choice in patients with urachal carcinoma. Due to complications and to reduce hospital stay from open surgery, minimally invasive approaches are desirable. Nowadays, robotic-assisted surgery has become increasingly popular, and robot-assisted cystectomy can be performed in patients with urachal carcinoma with low complication rates. Methods We performed a systematic review to search for studies that evaluated patients who underwent robotic-assisted surgery for urachal carcinoma. The outcomes of interest were the type of cystectomy performed, whether there was umbilicus resection, total operative time, console time, intraoperative complications, estimated blood loss, postoperative complications, time of hospitalisation, positive surgical margins and the presence of documented tumour recurrence. Results In this study, we evaluated three cohorts comprising a total of 21 patients. The median follow-up period ranged from 8 to 40 months. Medium age was between 51 and 54 years, with a majority (63.1%) being male. One patient (5.2%) underwent a radical cystectomy, and 19 patients (94.7%) underwent to partial cystectomy. Umbilical resections were performed in all cases, and pelvic lymphadenectomy in 14 cases (73.6%). Recurrence occurred in three patients at a median of 17 months postoperation, two cases in the trocar insertion site. Additionally, there was one death, which was attributed to postoperative cardiovascular complications. Conclusion Robotic-assisted partial cystectomy has a low incidence of adverse outcomes in patients with urachal carcinoma. Controlled studies, ideally randomised, are warranted to establish the comparative efficacy and safety of the robotic-assisted cystectomy approach relative to open surgery.
  • article 6 Citação(ões) na Scopus
    Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma
    (2016) MOTA, Jose Mauricio; SCARANTI, Mariana; FONSECA, Leonardo G.; TOLOI, Diego Araujo; CAMARGO, Veridiana Pires de; MUNHOZ, Rodrigo Ramella; FEHER, Olavo; HOFF, Paulo M.
    Background: Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of vascular origin that typically arises from the skin or soft tissues as a solitary tumor. The optimal therapy for this disease is still unknown. We report the case of an adult patient presenting with metastatic KHE of the spleen, who had a partial response after treatment with paclitaxel. Case Presentation: A 36-year-old man presented in November 2012 with a nontraumatic rupture of the spleen. A splenectomy was performed, and the pathology was consistent with a nonspecific vascular proliferation. Follow-up scans revealed lytic bone lesions and liver metastasis. A biopsy of the liver was performed and confirmed KHE. The decision was made to proceed with treatment with gemcitabine and docetaxel, which was discontinued due to myelotoxicity. The patient was then transferred to our institution, and a pathology review supported the diagnosis of metastatic KHE. His disease remained stable until February 2014, when he developed progression in the liver. Chemotherapy was restarted with paclitaxel, and a partial response was documented after 3 cycles. Unfortunately, disease progression occurred after 24 weeks, and subsequent treatments included prednisone, doxorubicin, interferon-a, gemcitabine, and ifosfamide, without any response. The patient developed Kasabach-Merritt phenomenon and passed away 1 week later due to a major gastrointestinal bleeding. Conclusions: This case report suggests that paclitaxel could be considered as a treatment option for advanced KHE, a rare condition for which no standard treatment exists. (C) 2016 The Author(s) Published by S. Karger AG, Basel
  • article 0 Citação(ões) na Scopus
    Scoring system for prediction of overall survival in patients with renal cell carcinoma T3aN0M0
    (2024) SUARTZ, Caio Vinicius; CORDEIRO, Mauricio Dener; CARVALHO, Paulo Afonso de; GALLUCCI, Fabio Pescarmona; RIBEIRO-FILHO, Leopoldo Alves; CARDILI, Leonardo; SIVARAMAN, Arjun; AUDENET, Francois; MOTA, Jose Mauricio; NAHAS, William Carlos
    ObjectiveWe aim to create a new score to predict postoperative overall survival in patients with nonmetastatic T3aN0 renal cell carcinoma.MethodsWe reviewed the clinical data of adult patients who underwent radical nephrectomy for renal cell carcinoma between December 2007 and January 2022 in a single tertiary oncological institution. Clinical characteristics, clinical-pathological staging and histopathological characteristics were analysed. Survival analyses were determined using the Kaplan-Meier curve. A nomogram was established using Cox proportional hazard regression to identify the prognostic factors affecting the overall survival. The area under the curve, calibration curves and decision curve analysis were used to evaluate prognostic efficacy.ResultsWe analyzed 362 patients classified as pT3aN0M0 stage with a median follow-up of 40 months. According to Cox univariate and multivariate analyses, weight loss greater than 5% in 6 months before surgery, stage V chronic kidney disease after radical nephrectomy, sarcomatoid pattern, and coagulative tumor necrosis were identified as predictors of overall survival. We developed a score and performed internal and external validation. The time-dependent receiver operating characteristic curve, area under the curve value and calibration curve analysis showed good prediction ability of the score. The nomogram can effectively predict and stratify overall survival after radical nephrectomy in patients with pT3aN0M0 renal cell carcinoma.ConclusionPatients with pT3aN0MO renal cell carcinoma exhibited different characteristics, and those with unfavourable characteristics deserve greater attention during follow-up. This nomogram provides an accurate prediction of overall survival after radical nephrectomy.
  • conferenceObject
    High-dose chemotherapy with autologous stem cell transplant (HDCT) for patients (pts) with advanced germ-cell tumors (aGCT): Real-world evidence from a tertiary cancer center in Brazil.
    (2023) POLHO, Gabriel Berlingieri; CUNHA, Mateus Trinconi; XAVIER, Erick Menezes; SILVA, Jamile Almeida; HIDALGO FILHO, Cassio Murilo Trovo; CRUSOE, Nathalia de Souza Del Rey; ATANAZIO, Marcelo Junqueira; HORITA, Vivian; FREITAS, Guilherme Fialho de; MUNIZ, David Queiroz Borges; ROCHA, Vanderson Geraldo; MOTA, Jose Mauricio
  • conferenceObject
    Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.
    (2022) BASTOS, Diogo Assed; COELHO, Rafael; CARDILI, Leonardo; GALIZA, Felipe; ILARIO, Eder Nisi; VIANA, Ublio; MURTA, Claudio Bovolenta; GUGLIELMETTI, Giuliano; CORDEIRO, Mauricio; PONTES JR., Jose; MUNIZ, David Queiroz Borges; SILVA, Jamile Almeida; MOTA, Jose Mauricio; FREITAS, Guilherme Fialho De; LEITE, Katia Ramos Moreira; BUCHPIGUEL, Carlos Alberto; NAHAS, William Carlos
  • article 280 Citação(ões) na Scopus
    Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner
    (2018) WANDERLEY, Carlos W.; COLON, David F.; LUIZ, Joao Paulo M.; OLIVEIRA, Francisco F.; VIACAVA, Paula R.; LEITE, Caio A.; PEREIRA, Janaina A.; SILVA, Camila M.; SILVA, Cassia R.; SILVA, Rangel L.; SPECK-HERNANDEZ, Cesar A.; MOTA, Jose M.; ALVES-FILHO, Jose C.; LIMA-JUNIOR, Roberto C.; CUNHA, Thiago M.; CUNHA, Fernando Q.
    Paclitaxel is an antineoplastic agent widely used to treat several solid tumor types. The primary mechanism of action of paclitaxel is based on microtubule stabilization inducing cell-cycle arrest. Here, we use several tumor models to show that paclitaxel not only induces tumor cell-cycle arrest, but also promotes antitumor immunity. In vitro, paclitaxel reprogrammed M2-polarized macrophages to the M1-like phenotype in a TLR4-dependent manner, similarly to LPS. Paclitaxel also modulated the tumor-associated macrophage (TAM) profile in mouse models of breast and melanoma tumors; gene expression analysis showed that paclitaxel altered the M2-like signature of TAMs toward an M1-like profile. In mice selectively lacking TLR4 on myeloid cells, for example, macrophages (LysM-Cre(+/-)/TLR4(fl/fl)), the antitumor effect of paclitaxel was attenuated. Gene expression analysis of tumor samples from patients with ovarian cancer before and after treatment with paclitaxel detected an enrichment of genes linked to the M1 macrophage activation profile (IFN gamma-stimulated macrophages). These findings indicate that paclitaxel skews TAMs toward an immunocompetent profile via TLR4, which might contribute to the antitumor effect of paclitaxel and provide a rationale for new combination regimens comprising paclitaxel and immunotherapies as an anticancer treatment. Significance: This study provides new evidence that the antitumor effect of paclitaxel occurs in part via reactivation of the immune response against cancer, guiding tumor-associated macrophages toward the M1-like antitumor phenotype. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/20/5891/F1.large.jpg. (C) 2018 AACR.
  • article 451 Citação(ões) na Scopus
    Wnt/beta-catenin pathway: modulating anticancer immune response
    (2017) PAI, Sachin Gopalkrishna; CARNEIRO, Benedito A.; MOTA, Jose Mauricio; COSTA, Ricardo; LEITE, Caio Abner; BARROSO-SOUSA, Romualdo; KAPLAN, Jason Benjamin; CHAE, Young Kwang; GILES, Francis Joseph
    Wnt/beta-catenin signaling, a highly conserved pathway through evolution, regulates key cellular functions including proliferation, differentiation, migration, genetic stability, apoptosis, and stem cell renewal. The Wnt pathway mediates biological processes by a canonical or noncanonical pathway, depending on the involvement of beta-catenin in signal transduction. beta-catenin is a core component of the cadherin protein complex, whose stabilization is essential for the activation of Wnt/beta-catenin signaling. As multiple aberrations in this pathway occur in numerous cancers, WNT-directed therapy represents an area of significant developmental therapeutics focus. The recently described role of Wnt/beta-catenin pathway in regulating immune cell infiltration of the tumor microenvironment renewed the interest, given its potential impact on responses to immunotherapy treatments. This article summarizes the role of Wnt/beta-catenin pathway in cancer and ongoing therapeutic strategies involving this pathway.
  • article 0 Citação(ões) na Scopus
    Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503) (vol 4, pg 543, 2021)
    (2022) MORRIS, Michael J.; MOTA, Jose Mauricio; LACUNA, Kristine; HILDEN, Patrick; GLEAVE, Martin; CARDUCCI, Michael A.; SAAD, Fred; COHN, Erica D.; FILIPENKO, Julie; HELLER, Glenn; SHORE, Neal; ARMSTRONG, Andrew J.; SCHER, Howard I.
  • bookPart
    Câncer de próstata
    (2023) MOTA, José Mauricio; MUNIZ, David Queiroz Borges; CRUSOé, Nathalia; FREITAS, Guilherme Fialho de
  • article 27 Citação(ões) na Scopus
    Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma
    (2019) FALCAO, Camila Kruschewsky; CABRAL, Marina Campos Simoes; MOTA, Jose Mauricio; ARBACHE, Samia Trigo; COSTA-RIQUETTO, Aline Dantas; MUNIZ, David Queiroz Borges; CURY-MARTINS, Jade; ALMEIDA, Madson Q.; KACZEMORSKA, Priscilla Cukier; NERY, Marcia; TELES, Milena Gurgel
    Context: Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report a case of acquired generalized lipodystrophy possibly associated with nivolumab. Case Description: A woman was referred to our Endocrinology Department for uncontrolled diabetes mellitus. At 50 years of age, she was diagnosed with type 2 diabetes after a routine laboratory test and her diabetes was well controlled with low doses of metformin. In 2010, she was diagnosed with clear cell renal carcinoma. The cancer progressed in the following years, leading to the initiation of treatment with nivolumab in 2017. Two months later she presented with facial lipoatrophy, with loss of the buccal fat pads and prominent zygomatic arch. Her neck, shoulders, arms, and buttocks were also affected. Her diabetes control worsened. She received maximal doses of metformin and pioglitazone and was administered 1.5 units/kg/d insulin. Subcutaneous biopsy of medial surface of the arm revealed chronic lobular panniculitis. Despite nivolumab's possible involvement in the onset of lipodystrophy, the maintenance of nivolumab therapy was justified by the observed reduction in the progression of the cancer, combined with the lack of an alternative chemotherapy. The therapy was withdrawn after 8 months of treatment because of grade 3 hepatitis. Conclusion: Anti-PD1 therapy has great potential. Early recognition of the onset of unusual collateral effects is important to improve decision making regarding the treatment of patients with tumors.